HomeGeneticsConditionStargardt macular degeneration
Back to Condition
Stargardt macular degeneration
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Condition

Stargardt macular degeneration

Stargardt macular degeneration is a genetic eye disorder that causes progressive vision loss by damaging the macula, the small area of the retina responsible for sharp, detailed vision.

Overview

Stargardt macular degeneration affects the retina, the light-sensitive tissue at the back of the eye. Specifically, it targets the macula, which is essential for tasks like reading, driving, and recognizing faces. In most cases, a fatty yellow pigment called lipofuscin accumulates in cells underlying the macula, eventually damaging the cells critical for clear vision.

Symptoms

Signs and symptoms typically appear in late childhood to early adulthood and worsen over time. These include:

  • Progressive vision loss.
  • Problems with night vision, making navigation in low light difficult.
  • Impaired color vision.

Causes

The condition is primarily caused by variants in the ABCA4 gene, and less frequently by variants in the ELOVL4 gene.

  • ABCA4 gene: This gene produces a protein that transports toxic substances out of photoreceptors. When the protein is dysfunctional, these substances build up as lipofuscin, leading to cell death.
  • ELOVL4 gene: This gene is involved in creating very long-chain fatty acids. Variants lead to the formation of protein clumps (aggregates) that interfere with retinal cell function.

Inheritance

The inheritance pattern depends on the gene involved:

  • ABCA4 variants: Inherited in an autosomal recessive pattern, where both copies of the gene must have a variant.
  • ELOVL4 variants: Inherited in an autosomal dominant pattern, where one copy of the altered gene is sufficient to cause the disorder.

Frequently Asked Questions

Limiting vitamin A intake (especially in high‑dose supplements) is advised because vitamin A can worsen lipofuscin accumulation. A diet low in saturated fats and rich in antioxidants (vitamins C, E, lutein, zeaxanthin) may support retinal health, but no specific diet has proven to halt progression. Regular monitoring by an ophthalmologist is essential.
Low‑vision aids such as magnifying lenses, high‑contrast fonts, screen‑reader software, and adaptive lighting help maintain independence. Occupational therapy can teach strategies for reading, driving, and recognizing faces. Using assistive devices like voice‑activated assistants and large‑print materials can also improve quality of life.
comprehensive eye exam that includes a dilated fundus examination, fundus autofluorescence imaging to detect lipofuscin buildup, and electroretinography (ERG) to assess retinal function is standard. Genetic testing for ABCA4 or ELOVL4 mutations can confirm the diagnosis and help predict disease course.
Currently, there is no FDA‑approved disease‑modifying therapy. Gene‑replacement trials using viral vectors to deliver a functional ABCA4 gene are in early phases. Other experimental approaches include retinal prostheses, stem‑cell‑derived retinal implants, and pharmacologic agents that reduce lipofuscin. Patients should discuss trial eligibility with a retinal specialist.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

Meyahealth

Ⓒ 2026. All rights reserved by MEYA